$ News

Roche purchases shares in tender offer for 89bio, Inc

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

Assessing 89bio (ETNB) Valuation Following a 60% Share Price Rally

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal

89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger

Raymond James cuts 89bio to “market perform” after Roche’s $14.50 per share deal

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Roche's 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP-1 Wars

89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion.

Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout

Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds

Roche Expands Cardiometabolic Pipeline With 89bio Acquisition

89bio, Inc. Announces Agreement to be Acquired by Roche

A Closer Look at 89bio (ETNB) Valuation Following Recent Share Price Drift

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

H.C. Wainwright Backs 89bio (ETNB) with Buy Rating

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript